Cargando…
Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
Dipeptidyl peptidase (DPP)-4 inhibitors, or gliptins, are a class of oral hypoglycemic drugs that have been widely used as a second-line treatment for type 2 diabetes. Gliptins, which were introduced for clinical use a decade ago, have been shown to be beneficial against nonalcoholic fatty liver dis...
Autores principales: | Wang, Zheng, Park, Hansu, Bae, Eun Ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Physiological Society and The Korean Society of Pharmacology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819900/ https://www.ncbi.nlm.nih.gov/pubmed/31680767 http://dx.doi.org/10.4196/kjpp.2019.23.6.459 |
Ejemplares similares
-
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018) -
Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
por: Kruger, Annie J., et al.
Publicado: (2018) -
Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020) -
Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
por: Diaz Soto, Maria Paula, et al.
Publicado: (2020) -
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)